I recently described an epigenetic biomarker of aging based on DNA methylation (DNAm) levels [1] . Unfortunately, I made a software coding error in my analysis of the cancer data, but not of the non-cancer tissue data. The error effectively added an offset term to the age estimates. All of my results from [1] that involve noncancerous tissue or cancer cell lines remain valid but I have to report some corrections for the cancer tissue data. In particular, I have to retract the statement that cancer is associated with an increased DNA methylation age (i.e. positive age acceleration) in most cancer types. In fact, while some cancer types show positive age acceleration, others exhibit negative age acceleration. I deeply regret this software coding error. The error arose from me using the wrong age calibration function for the cancer tissue data sets, which led to a systematic overestimation of DNA methylation age (Figure 1) .
Fortunately, all of the other statements about cancer remain intact since the coding error effectively added an offset term to predicted age that changed little with chronological age (Figure 1 ). I am comforted by the fact that most of the reported results for cancer become even more significant, including the following. First, the results for cancer tissues are now more congruent with those obtained for cancer cell lines (which remain unchanged). Second, the age predictor leads to a much lower error in cancer tissues (now 16 years). Third, the results for TP53 become more significant, that is TP53 mutations are associated with lower age acceleration in colorectal cancer.
As a result of this error, the following Figures and Additional files are incorrect in the published paper, and correct versions are presented here: Below, for sections of the original paper that are affected by the error, I explain how the corrected results are different from those that were reported.
DNAm age of cancer tissue versus tumor morphology
In the original paper, I reported the correlation between DNAm age and chronological age as being 0.15 (P = 1.0×10 −29 ). The correct correlation is 0.16 (p = 2.5×10 −33 ; Additional file 2A). In addition, I reported that each cancer/affected tissue shows evidence of significant age acceleration. Instead, out of 20 cancer/affected tissues, only 6 exhibit positive age acceleration effects while others Correct DNAmAge Old, incorrect estimate of DNAmAge Figure 1 Evaluating the effect of the error on the DNAm age estimate in the cancer samples. The old, incorrect estimate of DNAm age (y-axis) versus the correct estimate (x-axis). Note that the two estimates are highly correlated (r = 0.98), which explains why most results are unaffected, but the old estimate is poorly calibrated, which leads to an average bias of 42 years. After using the correct estimate, I can no longer observe a positive age acceleration effect in cancer.
Figure 2
Age acceleration versus number of somatic mutations in the TCGA data. Mutation data from TCGA were used to count the number of mutations per cancer sample. A) Age acceleration versus (log transformed) mutation count per sample across all cancers. Note that this analysis is confounded by cancer/tissue type. B-P) A significant negative relationship between age acceleration and number of somatic mutations can be observed in the following seven affected tissues/cancers: C) bone marrow (AML), D) breast carcinoma (BRCA), G) kidney (KIRC), H) kidney (KIRP), K) ovarian cancer (OVAR), L) prostate (PRAD), and O) thyroid (THCA). No significant relationship could be found in the following six cancer types: F) colon carcinoma (COAD), I) lung adenocarcinoma (LUAD), J) lung squamous cell carcinoma (LUSC), P) uterine endometrioid, M) rectal cancer (READ), N) skin. Due to the low sample size, the results are inconclusive for B) bladder cancer and E) cervical cancer. Each point corresponds to a DNA methylation sample (cancer sample from a human subject) analogous to Additional file 1. The x-axis reports the log transformed (base 10) number of mutations observed per sample. The figure titles report the biweight midcorrelation, which is a robust measure of correlation. often show negative age acceleration effects, i.e. they appeared younger than expected ( Figure 2B ).
The following original statement remains unchanged: "Tumor morphology (grade and stage) has only a weak relationship with age acceleration in most cancers: only 4 out of 33 hypothesis tests led to a nominally (p < 0.05) significant result (Additional file 3)".
But I have to retract the statement that only the negative correlation between stage and age acceleration in thyroid cancer remains significant after a applying a Bonferroni correction. It turns out that the uncorrected p-value of 0.0048 (Additional file 3Z) is not significant after multiplying it by 33.
Cancer tissues with high age acceleration exhibit fewer somatic mutations
The original statement that the number of mutations per cancer sample tends to be inversely correlated with age acceleration (Figure 2A ) remains unchanged.
But I have to retract the claim that one can observe a significant negative relationship between age acceleration and the number of somatic mutations in thyroid cancer ( Figure 2O ).
TP53 mutations are associated with lower age acceleration Additional file 5 presents the genes whose mutation has the strongest effect on age acceleration. The following original statement remains unchanged: "Strikingly, TP53 was among the top 2 most significant genes in 4 out of the 13 cancer data sets".
But I have to revise the following paragraph: "Further, TP53 mutation is associated with significantly lower age acceleration in five different cancer types including AML (p = 0.0023), breast cancer (p = 1.4E-5 and p = 3.7E-8), ovarian cancer (p = 0.03), and uterine corpus endometrioid (p = 0.00093). Further, marginally significant result can be observed in lung squamous cell carcinoma and colorectal cancer (p = 0.073, below). I could only find one cancer type (GBM) where mutations in TP53 are associated with a nominally significant increased age acceleration (p = 0.02)". as follows: TP53 mutation is associated with significantly lower age acceleration in six data sets (Additional file 6) including AML (P = 0.0041), breast cancer (P = 7.8×10 −12 and P = 1.4×10 −12 ), ovarian cancer (P = 0.04), uterine corpus endometrioid (P = 0.0012), and colorectal cancer (P = 0.036, Figure 4B ). Further, marginally significant result can be observed in lung squamous cell carcinoma (P = 0.088 Additional file 6G).
Somatic mutations in steroid receptors accelerate DNAm age in breast cancer
The following original statement remains unchanged: "Age acceleration differs greatly across different breast cancer types ( Figure 4N ): Luminal A tumors (typically ER+ or PR+, HER2-, low Ki67), show the highest positive age acceleration".
But I retract the statement that luminal B tumors (typically ER+ or PR+, HER2+ or HER2-with high Ki67) show a similar effect.
Proto-oncogenes affect DNAm age in colorectal cancer
The p-value in the following statement "Echoing previous results, TP53 mutations appear to be associated with decreased age acceleration (p = 0.073)" needs to be revised to (p = 0.036, Figure 4B ).
The p-value in the following statement "Promoter hypermethylation of the mismatch repair gene MLH1 leads to the most significant increase in age acceleration (P = 5.7×10 −5 )" needs to be revised to (p = 3.9×10 −7 , Figure 4D ).
The p-value in the following statement "The CpG island methylator phenotype, defined by exceptionally high cancer-specific DNA hypermethylation, is also significantly (p = 3.5×10 −5 ) associated with age acceleration" needs to be revised to (p = 3.6×10 −7 , Figure 4F ).
DNAm age in glioblastoma multiforme (GBM)
The p-value in the following statement "Interestingly, age acceleration in GBM samples is highly significantly (p = 3.3×10 −7 ) associated with certain mutations in H3F3A" needs to be revised to (p = 0.0015, Figure 4J ).
The p-value in the following statement "…age acceleration varies significantly (p = 2×10 −7 ) across the GBM subtypes defined in (Sturm et al 2012)" needs to be revised to (p = 1.2×10 −7 , Figure 4L ). 
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AgeAccel. FLT3 mutation RAS mutation (activ) IDH1 mutation A ColorectalGSE25062 p = 0.00029 B ColorectalGSE25062 p = 0.036 C ColorectalGSE25062 p = 0.007 D ColorectalGSE25062 p = 3.9e−07 E BRAF,TP53,KRAS,MLH1 p = 1.6e−05 F ColorectalGSE25062 p = 3.6e−07 Figure 4 Age acceleration in colorectal cancer, GBM and AML. A-F) report results for colorectal cancer. Mean age acceleration (y-axis) in colorectal cancer versus mutation status (denoted by +) in A) BRAF, B) TP53, C) K-RAS. D) Promoter hyper methylation of the mismatch repair gene MLH1 (denoted +) is significantly associated with age acceleration. E) Mean age acceleration across different patient groups defined by combinations of BRAF, TP53, K-RAS, MLH1 status. The first bar reports the age acceleration in normal adjacent colorectal tissue from cancer patients but the sample size of 4 is rather low. F) CpG island methylator phenotype is associated with age acceleration. G-R) present results for various genomic abnormalities in glioblastoma multiforme. J) H3F3A mutations versus age acceleration. Samples with a G34R mutation have the highest age acceleration. Panels S-W (last row) show results for various genomic aberrations in acute myeloid leukemia. X) Thyroid cancer age acceleration versus RAS family mutation status is inconclusive since mutation status was largely unknown.
